Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Medical Devices

Background:

• Intracavitary left ventricular (LV) obstruction is a key factor in hypertrophic cardiomyopathy (HCM) outcomes.
• Mid-cavity obstructive HCM, sometimes with LV aneurysm, presents challenges for standard surgical intervention.
• This specific obstruction pattern affects a minority of HCM patients and may indicate a poorer prognosis.

Purpose of the Study:

• To evaluate the long-term efficacy of dual chamber (DDD) pacemakers in managing mid-cavity obstructive HCM.
• To assess the impact of DDD pacing on symptoms, functional class, and hemodynamic parameters in this patient subset.

Main Methods:

• A study involving 14 patients with mid-cavity obstructive HCM (mean age 34 years).
• Patients received DDD pacemakers and were assessed via cardiac catheterization before and after therapy (6 months to 1 year follow-up).
• Drug therapy was discontinued during the evaluation period.

Main Results:

• All patients experienced symptomatic improvement, with a significant reduction in NYHA functional class (from 2.8 to 1.9, P < 0.0005).
• Intracavitary LV pressure gradients decreased significantly (from 84 to 43 mmHg, P < 0.0005).
• A significant reduction in apical LV systolic pressure and a trend towards increased exercise tolerance were observed.

Conclusions:

• Chronic DDD pacing provides substantial symptomatic and hemodynamic benefits for patients with mid-cavity obstructive HCM.
• This therapy is a valuable option for patients with this specific HCM subtype, where surgical options are less defined.